Novo Nordisk has appointed Jamey Millar, former CEO of Optum Specialty Holdings, as the drug company’s executive vice president of U.S. operations, effective Feb. 5.
In the role, Mr. Millar will oversee Novo Nordisk’s largest sales region, according to Novo Nordisk. The Denmark-based company, which is one of the world’s leading GLP-1 drug manufacturers, announced the executive management change Feb. 3 in its 2025 financial report.
Since 2021, Mr. Millar has served UnitedHealth Group’s OptumRx and Optum Specialty Holdings. Prior to those roles, he worked for GSK and Procter & Gamble for over 20 years, collectively.
The previous executive vice president of U.S. operations, Dave Moore, “decided to leave Novo Nordisk for personal reasons,” Novo Nordisk said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
